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A B S T R A C TObjective: This study aims to assess the costs associated with
hospital-acquired infections (HAIs) in a private tertiary care hospital
in northern India. Methods: This retrospective case-control study
covered four types of HAIs: urinary tract infections, ventilator-
associated pneumonia, bloodstream infections, and surgical site
infections. The ‘‘case’’ group comprised patients who had developed
HAIs, whereas the ‘‘control’’ group had patients who had not acquired
HAIs. The control group was matched with the case group on the
criteria of age, diagnosis, and severity of illness. Drugs’ acquisition
costs, hospital rental, consultation fees, investigation costs, and
antimicrobial costs were computed for patients over a period of 1
year, and comparisons were made between both the arms of the
study. The costs were also compared within the different HAIs.
Results: Of the four types of HAIs studied, the most commonly
encountered infection was bloodstream infection (38%). The pathogen
most frequently responsible for causing HAIs was Acinetobactersee front matter Copyright & 2013, International
r Inc.
.1016/j.vhri.2013.03.002
st: The authors have indicated that they have no
niper.ac.in.
ondence to: Pramil Tiwari, Department of Pharma
r 160062, Punjab, India.baumanii. Patients aged between 60 and 69 years were found to be
more susceptible to HAIs than the patients in other age groups.
Furthermore, the most common diagnosis of patients who developed
HAI was head injury followed by renal failure. Drugs’ acquisition
costs, rent, consultation fees, investigation costs, and antimicrobial
costs were significantly higher for cases than for controls (Po 0.001).
Drugs’ acquisition cost was the major contributor of the extra cost,
and antimicrobial drugs constituted almost half of it. Conclusions:
This study has provided evidence that the cost of drugs is a major
contributor to costs of HAIs in an Indian setting. Continuous surveil-
lance and prophylaxis is recommended for reducing HAIs.
Keywords: bloodstream infection, costs, hospital-acquired infections,
urinary tract infection, ventilator-associated infection.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Congregating a large number of patients under a single roof could
easily facilitate the transmission of infectious diseases from one
patient to another. The chances of developing an infection increases
manifold if the patient is immunocompromised or has an inserted
medical device (such as urinary catheter, ventilator, or central lines).
Approximately 5% of hospitalized patients experience a hospital-
acquired infection (HAI) [1]. HAI, according to the Centers for Disease
Control and Prevention guidelines, is a localized or systemic condi-
tion 1) that results from adverse reaction to the presence of an infec-
tious agent(s) or its toxin(s) and 2) that was not present or incubating
at the time of admission to the hospital [2]. HAIs are an important
public health problem in developing countries as well as in devel-
oped ones. HAI is known to be a major cause of high morbidity,
mortality, and economic consequences in hospitalized patients [1].
At any time, more than 1.4 million people worldwide suffer
from complications of infections acquired in the hospital [3].
HAIs could lead to any one or more of these: functional disability
and emotional stress to the patient, increased morbidity (serious
consequences and permanent disability), and prolongation of
hospital stay, which adds to the cost. Developed countries, over aperiod of time, have established standardized criteria for the
surveillance and control of HAIs. In developing countries, how-
ever, only limited results are available to understand the cost of
HAIs and there is a lack of surveillance of HAIs [4,5].
A retrospective case-control study, conducted at the cardio-
thoracic unit of a 200- bed Indian tertiary care hospital, has
provided evidence that patients with hospital-acquired bactere-
mia had a statistically significantly longer total hospital stay and
intensive care unit stay.
These results also demonstrated that hospital-acquired bac-
teremia significantly increases mortality and costs of hospital-
ization in lower-income developing countries. It was concluded
that the costs associated with HAIs are similar between devel-
oping and developed countries [6].
The aim of this study was to assess the costs associated with
HAIs in a private tertiary care hospital in northern India.Methods
The study was conducted at a private tertiary care hospital with a
capacity of 250 beds. It is understood that 70% of the patientsSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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patients were covered under a reimbursement scheme or insur-
ance. Annually, the hospital handles close to 20,000 inpatient
admissions.Study Design
It was a retrospective study wherein the patients were divided
into two groups:1.T
T
M
W
A
C
P
D
LThe ‘‘case’’ group included inpatients who had developed
an HAI.2. The ‘‘control’’ group included inpatients who had not devel-
oped an HAI.
The patients in the two arms were matched on the basis of
age, diagnosis, and severity of illness as evaluated by the Acute
Physiology and Chronic Health Evaluation IV scoring system [7].Time period
The records of patients admitted to the hospital from August
2008 to July 2009 were screened, and only those meeting the
inclusion and exclusion criteria were included in the study. An
HAI was defined as one that was neither present nor incubating
at the time of admission and occurred only after 48 hours of
admission to the hospital.Inclusion criteria
Inpatients 18 years or older, either sex, with a minimum hospital
stay of 48 hours were included. Only the culture-positive patients
were included.able 1 – Demographics and clinical profiles of cases an
Variable
Cases
otal number of patients 108
en 62 (57)
omen 46 (43)
verage age of patients (y), mean  SEM 60  1.7
hronic health comorbidities
Hypertension 28 (25.9
Diabetes 15 (13.8
Coronary artery disease 8 (7.4)
Asthma 4 (3.7)
Others 8 (7.4)
rofile of diagnoses
Head injury 31 (28)
Renal failure 22 (20)
Vascular 13 (12)
Respiratory 12 (11)
Liver 5 (4)
Gastric 4 (3)
Neoplastic 4 (3)
Others 17 (15)
ischarge status (n ¼ 108)
Improved 68 (62.9
LAMA 9 (8.4)
Death 31 (28.7
AMA, left against medical advice; SEM, standard error of the mean.Exclusion criteria
Patients who had infectious diseases or had only symptoms of
infection but had negative cultures were excluded. Furthermore,
patients with suspected clinical signs of HAI but with negative
culture report, patients admitted for labor, and patients with the
diagnosis of sepsis or septic shock were excluded.Data Collection
The data were collected by using patient medical records,
hospital information system, and other administrative databases
for costs and outcome analysis.
The data included patients’ information such as age, sex, date
of admission, discharge, surgery, diagnosis and surgical proce-
dure/intervention and date of infection, type of infection, patho-
gens, and antimicrobial drugs (AMDs) prescribed.
The data related to the cost component of the study included
package cost offered by the hospital plus costs incurred on
consumables, hospital room rent, drugs, investigations, blood
components, consultation, and AMDs.Data Analysis
The infection rates for central venous catheter-associated
bloodstream infection (BSI), catheter-associated urinary tract
infection(UTI), and ventilator-associated pneumonia (VAP) were
determined according to Centers for Disease Control and
Prevention-National Nosocomial Infections Surveillance defini-
tion [1,8].
All data were organized by using a spreadsheet. Continuous
variables were reported as average  standard error of the mean.
They were compared by using student’s t test, or the Wilcoxon
rank-sum test when departure from normality was observed.d controls.
n (%) P
Controls
108
86 (80) o0.001
22 (20) o0.001
61  1.5 0.30
) 43 (39.8) 0.0140
) 25 (23.1) 0.0388
8 (7.4) 0.5000
2 (1.8) 0.2034
10 (9.2) 0.4900
31 (28)
22 (20)
13 (12)
12 (11)
5 (4)
4 (3)
4 (3)
17 (15)
) 91 (84.2) o0.001
13 (12.1) o0.001
) 4 (3.7) o0.001
Table 2 – Microorganisms causing hospital-
acquired infections.
Microorganisms No. of cases
Acinetobacter. baumannii 45
Escherichia coli 16
Klebsiella pneumoniae 13
Enterococcus faecium 8
Staphylococcus aureus 7
Providencia rettegeri 6
Enterococcus faecalis 6
Pseudomonas aeruginosa 6
MRSA 4
Stenotrophomas maltophilia 3
Staphylococcus auricularis 2
Morganella morgani 2
Others 28
MRSA, Methicillin-resistant Staphylococcus aureus.
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The data of 30 patients were excluded from the study in
accordance with the exclusion criteria or unavailability of the
matched controls. Therefore, 216 patients’ data were analyzed to
achieve the objectives of this study.
Both the arms of the study were balanced, with108 patients in
each arm of the study. The case group had 57% male patients,
while the control group had 80% male patients. The two groups
were matched for average age, which was 61 years. Comorbidities
such as hypertension, diabetes, coronary artery disease, and
asthma were higher in the control group (Table 1).
It was observed that the highest proportion of HAIs occurred in
the age group of 60 to 69 years (27%) followed by those in the age
group of 70 to 79 years (23%). It was also found that patients with a
head injury or those who had undergone neurosurgeries were
more prone to develop HAI followed by patients having diseases
related to renal failure (28.7% and 20.4%, respectively; Table 1).
In the case group, 41 patients had a central line–associated BSI.
The number of patients with ventilator-associated infections and
catheter-associated UTIs was very close to each other (33 and 30,
respectively); only 4 patients had a surgical site infection (SSI).
Multiple HAIs were observed in 13 patients. The infection rate was
calculated for BSI, UTI, and VAP and represented as per 1000
device-days. The infection rate was found to be the highest for
VAP followed by BSI (6.8 and 3.2, respectively). Furthermore, it was
observed that it takes approximately 14 days on average post-
admission to develop an HAI (median 11 days; range 2–75 days).
In terms of outcomes, the discharge status was analyzed as
improved, left against medical advice (LAMA), or death of the
patients. It was found that 31 patients died in the case group
against 4 in the control group (Table 1). Furthermore, BSI was
found to be the largest contributor to mortality in the case group
followed by VAP, UTI, and SSI (15, 11, 4, and 1 deaths, respectively).
A total of 140 microorganisms were identified in 108 infec-
tions. A single pathogen was found in 75% of the cases, two
pathogens were found in 20% of the cases, and three pathogens
were isolated in 5% of the infections. In the hospital, Acinetobacter
baumannii and Escherichia coli were the two most common
causative microorganisms for HAIs (45 and 16 patients in the
case group, respectively; Table 2).
In the case group, imipenem was the most prescribed AMD
(66.6%) followed by metronidazole, piperacillin, levofloxacin, ami-
kacin, and linezolid. In the control group, however, ceftriaxone was
the most commonly prescribed AMD followed by ciprofloxacin and
piperacillinþ tazobactam (28%4 22%4 21%, respectively; Table 3).
Various costs counted in the study were drugs’ acquisition
cost, hospital room rent, investigation costs, consultation fees,
consumables cost, blood components cost, and prescribed anti-
microbial costs. The costs are represented as Indian rupees as
well as US dollars. It was assumed that US $1 equals Indian
rupees 55.
Of all the HAIs, VAP was found to be the most expensive HAI
followed by BSI, UTI, and SSI (Table 4). All the components of
costs were statistically significantly higher for cases than for
controls (P o 0.001). The cost for drugs’ acquisition was the main
cost driver, and the cost of AMDs constituted almost half of the
drugs’ acquisition cost. The total cost for the case group was
found to be more than five times that of the control group
(Table 5). The other cost drivers for increased cost in the case
group were investigations’ charges and hospital room rent. This
component is attributed to the increased length of stay.
As anticipated, the mortality in the case group was 28.7%
against 3.7% in the control group. This difference was found to be
significant. Table 6 represents a comparison of clinical outcomes
in the two arms of the study.Discussion
In India, the data on prevalence of HAIs are available [4] but there
is no published study analyzing the types of HAIs and the costs
associated with them. In this study, an attempt has been made to
cover the four major types of HAIs and to assess costs associated
with them.
The patients in both the groups were matched for age, diagnosis,
and severity of illness to minimize the confounding variables. The
patients who have had a road accident and had head injury were
more likely to be inserted devices such as urinary catheter, ventilator,
or central line. Hence, they were more prone to develop a HAI.
Therefore, most of the patients with HAI had diagnosis related to
neurosurgery, head injury, or head trauma. This is in agreement with
other results reported on a larger sample from multispecialty
hospitals [9,10]. The next most common diagnosis was renal failure;
patients with renal failure frequently undergo dialysis, and the
immunity level is reported to be low [11]. The next two common
diagnoses were the diseases of respiratory and vascular systems.
The most common type of HAI was BSIs. An earlier study has
also confirmed the fact that having central line–associated BSI is
the most common HAI followed by VAP and UTI [12]. These
results were in contrast with reports of the other two studies
indicating UTI as the most incident HAI [13,14]. The median
interval between admission of the patient to the hospital and the
development of HAI was 11 days, a finding that was consistent
with the results of Mitt et al.’ study [15] in which HAIs were
shown to have occurred after 13 days.
E. coli and A. baumannii were the most commonly found
microorganisms in the hospital leading to HAI followed by
Klebsiella pneumoniae (Table 2). In a retrospective analysis of
patients in a Chinese intensive care unit over a 5-year period,
Ding et al. [16] reported that A. baumannii and K. pneumoniae were
the most common pathogens [16]. Imipenem was the most
frequently prescribed antimicrobial agent because of the higher
prevalence of resistant bacteria such as A. baumannii (Table 3).
VAP contributed the highest total cost followed by BSI, UTI,
and SSI. It is because the charges for ventilator were also
included in VAP patients’ total cost. The cost of drugs was highest
in cases of BSI followed by VAP, UTI, and SSI (Table 4). The
percentage of antimicrobials used was the highest for BSI
followed by VAP and UTI.
The cost for drugs’ acquisition contributed little more than one
third of the extra cost (38%). For treating HAIs, mostly imipenem—
which is an expensive antimicrobial—was prescribed. Therefore,
Table 3 – Antimicrobial drugs prescribed.
Case group Control group
Antimicrobial(s) prescribed No. Antimicrobial(s) prescribed No.
Cilastatin þ imipenem 79 Ceftriaxone 30
Metronidazole 54 Ciprofloxacin 24
Piperacillin þ tazobactam, linezolid 46 Piperacillin þ tazobactam 23
Meropenem, tigecycline 45 Metronidazole, amikacin 22
Levofloxacin 40 Aomxicilin þ clavulanic acid 20
Vancomycin, ceftriaxone, teicoplanin, amikacin 37 Cilastatin þ imipenem 17
Ciprofloxacin 36 Vancomycin 12
Polymyxin B 31 Levofloxacin, cefuroxime 11
Amoxicilin þ clavulanic acid 27 Cefoperazone 10
Clindamycin 25 Azithromycin 9
Colistin 24 Ofloxacin 8
Cefepime 19 Meropenem 6
Cefuroxime 10 Others 29
Tobramycin, ceftazidine 11
Clarithromycin, pazufloxacin, 9
Cefoperazone, azithromycin, ampicillin 7
Aztreonam, prulifloxacin, ertapenem 5
Others 16
Note. Arranged in the decreasing order of instances of use.
Table 4 – Different types of average costs associated with four HAIs.
Component of cost,
mean  SEM
Average cost,
INR (US $)
VAP, INR (US $) BSI, INR (US $) UTI, INR (US $) SSI, INR (US $)
Total cost
704,175  57,804
(12,803  1,051)
756,895  107,277
(13,762  1,950)
691,334  90,302
(12,570  1,642)
686,457 122,035
(12,481 2,219)
533,738  68,044
(9,704  1,237)
Drugs’ acquisition
costs
266,764  30,063
(4,850  547)
272,342  39,562
(4,952  719)
294,940  57,877
(5,362  1,052)
257,646  60,372
(4,684  1,098)
1654,00  49,234
(3,007  895)
Rent, mean  SEM
131,718  13,977
(2,395  254)
137,196  30,572
(2,494  556)
110,274  18,186
(2,005  1,051)
13,8601  27,899
(2,520  507)
106,003  39,723
(1,927  722)
Consultation fees
27,908  3,325
(507  60)
31,840  7,504
(579  136)
22,946  4,208
(417  76)
31,011  6,496
(566  118)
23,073  11,187
(402  203)
Investigations
88,603  6,602
(1611  120)
96,065  13,001
(1747  236)
89,859  9,489
(1,634  172)
117,654  13,997
(2,139  254)
51,413  6,655
(935  121)
Antimicrobial drugs
129,400  10,543
(2353  192)
132,950  15,440
(2,417  281)
141,872  19,974
(2,580  363)
113,846  19,638
(2070  357)
124,408  51,767
(2,262  941)
Percentage of AMDs 49 49 48 45 75
Note. US $1 ¼ INR 55.
AMD, antimicrobial drug; BSI, bloodstream infection; HAIs, hospital-acquired infections; INR, Indian rupee; SEM, standard error of the mean;
SSI, surgical site infection; UTI, urinary tract infection; VAP, ventilator associated pneumonia.
Table 5 – Hospital treatment costs by different categories.
Different types of costs, mean  SEM Cases (n ¼ 108) Controls (n ¼ 108) P
Total cost 704,175  57,804 (12,803  1,051) 144,106  15,614 (2,620  284) o0.001
Drugs’ acquisition costs 266,764  30,063 (4,850  547) 29,482  5,156 (536  94) o0.001
Rent 131,718 13,977 (2,395  254) 36,419  4,572 (662  83) o0.001
Consultation fees 27,908  3,325 (507  60) 7,451  1,033 (135  19) o0.001
Investigations costs 88,603  6,602 (1611  120) 19,178  1,959 (349  36) o0.001
Antimicrobials costs 129,400  10,543 (2,353 192) 12,047  2,233 (219  41) o0.001
% of AMDs 49 41 o0.001
% of AMDs (median) 66 28 o0.001
Note. US $ ¼ INR 55.
AMDs, antimicrobial drugs; SEM, standard error of the mean.
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Table 6 – Clinical outcomes.
Clinical outcomes Cases (n ¼ 108) Controls (n ¼ 108) P
Improved, n (%) 68 (63) 91 (84.3) o0.001
LAMA, n (%) 9 (8.3) 13 (12) o0.001
Death, n (%) 31 (28.7) 4 (3.7) o0.001
UTI 13 0 –
VAP 33 0 –
BSI 36 100 –
SSI 25 0 –
Average LOS (d) 38 9 o0.001
Average ICU LOS (d) 27 5 o0.001
Average APACHE III score 41 40 0.908
Predicted average hospital mortality (APACHE IV) (%) 10 9 0.315
Predicted average ICU LOS days (APACHE IV) 5 4 0.141
APACHE, Acute Physiology and Chronic Health Evaluation; BSI, bloodstream infection; HAIs, hospital-acquired infections; ICU, intensive care unit;
LAMA, left against medical advice; LOS, length of stay; SSI, surgical site infection; UTI, urinary tract infection; VAP, ventilator-associated pneumonia.
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AMDs. This finding is in concurrence with previous results
[17,18].Conclusions
HAIs occurred more commonly in patients with head injury and
renal failure. The most commonly occurring type of HAI was BSI,
and the incidence rate was higher for VAP. The most common
pathogens causing HAIs were A. baumannii and E. coli. The most
commonly prescribed AMDs for HAIs was imipenem, while for
the matched patients, ceftriaxone and ciprofloxacin were com-
monly prescribed drugs.
As anticipated, the cost was higher for the hospital as well as for
patients due to HAIs. Drugs’ acquisition cost formed a major part of
the extra cost due to HAIs. In the drugs’ acquisition cost, almost
half of the share was for AMDs. The usage of AMDs was higher in
infected patients than in patients in the control group (49% vs. 41%).
VAP ranked first with respect to the economic burden.
This study shows that the cost of drugs is a major contributor
to the costs of HAIs as evidenced by five times higher costs in
cases than in controls. In view of this, it is recommended that
hospitals should take infection control as a high-priority area.
This can be achieved by the use of appropriate prophylaxis at
admission especially in ‘‘high-risk’’ and immunocompromised
patients, use of aseptic techniques, and complete sterilization of
surgical instruments before and during the surgical procedures.
Limitations
This study was performed by using data from 216 patients,
divided into two equal arms. The patients were not matched
for sex and comorbidities. Only the costs based on the docu-
mentation in the patient medical record could be captured.
Furthermore, it was not possible to take into account the hospital
costs for patients subsequently readmitted for infection-related
events beyond the review date. A further limitation of the study is
the accuracy and reporting of infections and their management
as documented in the medical records of each patient. Finally, it
is very well appreciated that the treatment costs would differ
from one country to another depending on the health financing
systems. In view of these, the present findings only reflect hard
evidence on the subject in an Indian hospital setting.
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